Trends in the use of cervical cancer screening tests in a large medical claims database, United States, 2013-2019.

Objective: To examine trends in the use of cervical cancer screening tests during 2013-2019 among commercially insured women.

Methods: The study population included women of all ages with continuous enrollment each year in the IBM MarketScan commercial or Medicare supplemental databases and without known history of cervical cancer or precancer (range = 6.9-9.

Good laboratory practices for molecular genetic testing for heritable diseases and conditions.

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) regulations, laboratory testing is categorized as waived (from routine regulatory oversight) or nonwaived based on the complexity of the tests; tests of moderate and high complexity are nonwaived tests. Laboratories that perform molecular genetic testing are subject to the general CLIA quality systems requirements for nonwaived testing and the CLIA personnel requirements for tests of high complexity. Although many laboratories that perform molecular genetic testing comply with applicable regulatory requirements and adhere to professional practice guidelines,specific guidelines for quality assurance are needed to ensure the quality of test performance.

Comparison of cytology proficiency testing: glass slides vs. virtual slides.

Objective: To compare proficiency testing in gynecologic cytology using glass slides vs. virtual slides.

Study Design: To compare performance, a sample of 111 individuals (pathologists = 52, cytotechnologists = 59) from participating in-state laboratories were administered 2 proficiency tests.